tradingkey.logo

enVVeno Medical Corp

NVNO
10.420USD
+1.070+11.44%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
6.02MValor de mercado
PerdaP/L TTM

enVVeno Medical Corp

10.420
+1.070+11.44%

Mais detalhes de enVVeno Medical Corp Empresa

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

Informações de enVVeno Medical Corp

Código da empresaNVNO
Nome da EmpresaenVVeno Medical Corp
Data de listagemMay 31, 2018
CEOBerman (Robert A)
Número de funcionários37
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 31
Endereço70 Doppler
CidadeIRVINE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92618
Telefone19492612900
Sitehttps://envveno.com/
Código da empresaNVNO
Data de listagemMay 31, 2018
CEOBerman (Robert A)

Executivos da empresa enVVeno Medical Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.64K
-140.00%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+23.00%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.64K
-140.00%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+23.00%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

Detalhamento da receita

Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: sáb, 7 de fev
Atualizado em: sáb, 7 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.92%
CM Management, LLC
5.45%
The Vanguard Group, Inc.
1.30%
Outro
71.72%
Investidores
Investidores
Proporção
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.92%
CM Management, LLC
5.45%
The Vanguard Group, Inc.
1.30%
Outro
71.72%
Tipos de investidores
Investidores
Proporção
Individual Investor
9.48%
Investment Advisor
8.80%
Private Equity
7.67%
Hedge Fund
7.22%
Investment Advisor/Hedge Fund
1.68%
Research Firm
1.18%
Venture Capital
0.18%
Outro
63.79%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
80
169.95K
25.92%
-68.67K
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Satterfield (Thomas A Jr)
1.82M
9.02%
+1.82M
--
Nov 14, 2025
Perceptive Advisors LLC
1.76M
8.7%
+474.07K
+36.89%
Sep 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
6.72%
+500.00K
+58.19%
Sep 30, 2025
CM Management, LLC
600.00K
2.97%
+600.00K
--
Sep 30, 2025
The Vanguard Group, Inc.
861.19K
4.26%
+162.85K
+23.32%
Sep 30, 2025
Berman (Robert Andrew)
222.24K
1.1%
+200.00K
+899.44%
Oct 17, 2025
Geode Capital Management, L.L.C.
201.24K
1%
+1.74K
+0.87%
Sep 30, 2025
J.P. Morgan Securities LLC
182.32K
0.9%
+22.00
+0.01%
Sep 30, 2025
Susquehanna International Group, LLP
154.47K
0.76%
+154.47K
--
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Data
Data ex-dividendo
Tipo
Proporção
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
KeyAI